Finance entity
Every one of those 1 sits in a single category, markets. StockAnalysis is most often covered alongside FDA, which appears in 1 of these 1 story. At 5, the average consequence score sits below the same-window beat average of 5.4.
Last mentioned: 21h ago
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, markets. StockAnalysis is most often covered alongside FDA, which appears in 1 of these 1 story. At 5, the average consequence score sits below the same-window beat average of 5.4. They are less corroborated than the beat average, carrying 2 original sources each against 2.2 for the same window. StockAnalysis appears in 1 tracked Finance story from September 7, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 29 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering StockAnalysis. Shared-story counts are live from our verified record — not editorial picks.
Coverage Highlights Market Divergence
Financial media report on the stock's surge and note some Wall Street price targets are more upbeat than Cramer's caution.
Cramer Calls NUVB 'Pure Speculation'
On CNBC's Mad Money, Jim Cramer warns Nuvation Bio trades on what pipeline drugs might do someday rather than steady revenue.
FDA Grants Fast Track Designation to Safusidenib
Nuvation Bio's experimental brain cancer drug safusidenib receives FDA Fast Track status for IDH1-mutant glioma.
Jim Cramer's September 3 'pure speculation' call on Nuvation Bio hits at a moment of momentum: shares rose on FDA Fast Track news and strong early IBTROZI adoption. Yet analysts forecast a full-year 2026 net loss, making the rally a contest between pipeline optionality and burn rate.
StockAnalysis is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
